Joshua Reed Sells 3,053 Shares of Scholar Rock (NASDAQ:SRRK) Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Joshua Reed sold 3,053 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $53.74, for a total value of $164,068.22. Following the completion of the transaction, the director directly owned 19,518 shares in the company, valued at $1,048,897.32. This represents a 13.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scholar Rock Trading Up 0.9%

NASDAQ SRRK traded up $0.48 during trading hours on Monday, hitting $55.36. 1,182,357 shares of the company’s stock were exchanged, compared to its average volume of 1,407,918. The stock has a 50-day simple moving average of $48.43 and a 200 day simple moving average of $46.59. Scholar Rock Holding Corporation has a 1-year low of $27.07 and a 1-year high of $56.54. The firm has a market cap of $6.63 billion, a price-to-earnings ratio of -15.42 and a beta of 0.67. The company has a current ratio of 8.64, a quick ratio of 8.64 and a debt-to-equity ratio of 0.71.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.01). During the same quarter in the previous year, the business earned ($0.67) earnings per share. On average, equities analysts forecast that Scholar Rock Holding Corporation will post -3.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. IFP Advisors Inc lifted its stake in shares of Scholar Rock by 294.1% in the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock valued at $27,000 after buying an additional 450 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Scholar Rock during the fourth quarter worth about $30,000. Summit Securities Group LLC acquired a new stake in shares of Scholar Rock in the 4th quarter worth about $31,000. EverSource Wealth Advisors LLC raised its holdings in shares of Scholar Rock by 151.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock worth $38,000 after acquiring an additional 525 shares during the last quarter. Finally, Hilton Head Capital Partners LLC bought a new position in Scholar Rock in the 4th quarter valued at about $44,000. Institutional investors and hedge funds own 91.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on SRRK shares. Wedbush boosted their target price on shares of Scholar Rock from $56.00 to $58.00 and gave the company an “outperform” rating in a research report on Wednesday, April 1st. JPMorgan Chase & Co. lifted their price target on shares of Scholar Rock from $47.00 to $50.00 and gave the company an “overweight” rating in a research note on Monday, March 16th. HC Wainwright upped their price objective on shares of Scholar Rock from $58.00 to $65.00 and gave the company a “buy” rating in a report on Friday, May 8th. Canaccord Genuity Group started coverage on shares of Scholar Rock in a research report on Monday, April 20th. They set a “buy” rating and a $62.00 price objective on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Scholar Rock in a research note on Tuesday, April 21st. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Scholar Rock currently has an average rating of “Buy” and a consensus price target of $56.00.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).